-
COST-EFFECTIVENESS OF SECOND-LINE TREATMENTS FOR ADVANCED AND METASTATIC GASTRIC CANCER IN THE IRISH HEALTHCARE-SETTING
Aug 11, 2026, 17:15 PM -
ECONOMIC IMPACT OF EMBOLIC AGENT CHOICE (LIQUID VS PARTICLES) IN MIDDLE MENINGEAL ARTERY EMBOLIZATION FOR CHRONIC SUBDURAL HEMATOMA : A NATIONAL HEALTHCARE SYSTEM PERSPECTIVE
Aug 11, 2026, 17:15 PM -
COMPARATIVE CLINICAL EFFICACY AND SAFETY OF EGFR-TKIS COMBINED WITH HERBAL MEDICINE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
Aug 11, 2026, 17:15 PM -
EU5 PAYER READINESS FOR ANTI-AGEING THERAPEUTICS: AWARENESS, CONCERN, AND ANTICIPATED REIMBURSEMENT HURDLES
Aug 11, 2026, 17:15 PM -
PUBLIC HEALTH IMPACT (PHI) OF RECOMBINANT ZOSTER VACCINE (RZV) FOR OLDER ADULTS AND IMMUNOCOMPROMISED PATIENTS IN BRAZIL
Aug 11, 2026, 17:15 PM -
CONTINUOUS EVIDENCE ORCHESTRATION: A HUMAN-GOVERNED, MCP-CONNECTED MULTI-AGENT GENAI PIPELINE FOR HEOR AND HTA
Aug 11, 2026, 17:15 PM -
IMMUNOGLOBULIN PRICE DYNAMICS ACROSS MAJOR MARKETS: EVIDENCE OF SUPPLY-DEMAND PRESSURE BEYOND INFLATION
Aug 11, 2026, 17:15 PM -
WHAT IS THE RIGHT COMPARATOR WHEN NO STANDARD EXISTS? A LIVING EVIDENCE APPROACH TO JCA PLANNING IN EARLY-STAGE PROSTATE CANCER
Aug 11, 2026, 17:15 PM -
THE COVIDENCE RELEVANCE RANKING TOOL FOR ACCELERATING SCREENING IN LITERATURE REVIEWS
Aug 11, 2026, 17:15 PM -
FROM POLICY RECOGNITION TO IMPLEMENTATION READINESS: A GLOBAL ANALYSIS OF NATIONAL BREAST CANCER CONTROL POLICIES ACROSS 194 WHO MEMBER STATES
Aug 11, 2026, 17:15 PM -
AVERAGE SALES PRICE AS A FAIRER BENCHMARK FOR MOST-FAVORED-NATION DRUG PRICING: A US-CANADA-GERMANY SPECIALTY-DRUG BASKET ANALYSIS
Aug 11, 2026, 17:15 PM -
FIVE CLINICALLY DISTINCT CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PRESCRIBER PERSONAS IDENTIFIED VIA UNSUPERVISED MACHINE LEARNING USING NORSTELLALINQ REAL-WORLD DATA
Aug 11, 2026, 17:15 PM -
QUANTIFYING REAL-WORLD CORTICOSTEROID BURDEN IN MYASTHENIA GRAVIS TREATED WITH NOVEL BIOLOGIC THERAPIES
Aug 11, 2026, 17:15 PM -
CAN NATIONAL EARLY SCIENTIFIC ADVICE SUPPORT JCA READINESS IN THE ABSENCE OF JOINT SCIENTIFIC CONSULTATION?
Aug 11, 2026, 17:15 PM -
WHY IS CAREGIVER HEALTH-RELATED QUALITY OF LIFE STILL EXCLUDED FROM CANCER HEALTH TECHNOLOGY ASSESSMENT?
Aug 11, 2026, 17:15 PM -
USES AND IMPACTS OF REAL-WORLD DATA (RWD) ON THE HAUTE AUTORITE DE SANTE
Aug 11, 2026, 17:15 PM -
BUILDING TRUST IN REAL-WORLD EVIDENCE: VALIDATION OF DATA, METHODS AND AI SOLUTIONS IN EUROPEAN CANCER CENTRES
Aug 11, 2026, 17:15 PM -
AN UNANCHORED MATCHING-ADJUSTED INDIRECT COMPARISON OF OVERALL SURVIVAL WITH RETIFANLIMAB PLUS CARBOPLATIN-PACLITAXEL VERSUS CARBOPLATIN-PACLITAXEL IN ADVANCED SQUAMOUS CELL ANAL CARCINOMA
Aug 11, 2026, 17:15 PM -
GENE THERAPY AUTHORIZATIONS AND ORPHAN DRUG DESIGNATIONS BY THE FDA AND EMA
Aug 11, 2026, 17:15 PM -
MICROSIMULATION OF THE NATURAL HISTORY OF STAGE II/III COLORECTAL CANCER AND EVALUATION OF FOLLOW-UP TESTING STRATEGIES (MONET-MODEL)
Aug 11, 2026, 17:15 PM
